Haematologica, 2019 Hemophilia A is a rare hemorrhagic disorder caused by the lack of functional pro-coagulant factor VIII. Factor VIII replacement therapy in patients with severe hemophilia A results in the development of inhibitory anti-factor VIII IgG in up to 30% of ...
Sandrine Delignat +7 more
doaj +1 more source
Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells [PDF]
, 2009 Background Treatment options for metastatic renal cell carcinoma (RCC) are limited due to resistance to chemo- and radiotherapy. The development of small-molecule multikinase inhibitors have now opened novel treatment options.
Natsheh, Iyad Y. M. +15 more
core +2 more sources
Bruton tyrosine kinase inhibitors as potential therapeutic agents for COVID-19: A review
Metabolism Open, 2021 Coronavirus disease 2019 (COVID-19) is first detected in December 2019 in Wuhan, China which is a new pandemic caused by SARS-COV-2 that has greatly affected the whole world.
Zemene Demelash Kifle
doaj +1 more source
The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines [PDF]
, 2009 Background Imatinib mesylate, a selective inhibitor of Abl tyrosine kinase, is efficacious in treating chronic myeloid leukaemia (CML) and Ph+ acute lymphoblastic leukaemia (ALL).
Schwarz, Kerstin +12 more
core +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023 Background There are limited data on risk of arrhythmias among patients with lymphoproliferative disorders. We designed this study to determine the risk of atrial and ventricular arrhythmia during treatment of lymphoma in a real‐world setting.
Saadia Sherazi +10 more
doaj +1 more source
The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
Clinical Hematology International, 2022 The use of Bruton Tyrosine Kinase (BTK) inhibitors in Waldenström’s Macroglobulinemia (WM) is evolving. Ibrutinib, a first-generation BTK inhibitor, is currently approved for use in frontline and relapsed/refractory disease.
Obada Ababneh +4 more
doaj +1 more source
Evolution of breast cancer therapeutics: Breast tumour kinase’s role in breast cancer and hope for breast tumour kinase targeted therapy [PDF]
, 2014 This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). © 2014 Baishideng Publishing Group Inc.There have been significant improvements in the detection
Hussain, HA, Harvey, A
core +1 more source
Ibrutinib in primary central nervous system diffuse large B-cell lymphoma
CNS Oncology, 2020 The standard regimen for the treatment of newly diagnosed primary CNS lymphoma (PCNSL) remains regimens that contain high-dose methotrexate (MTX). While these regimens can provide control for some patients, there is a dearth of options for the treatment ...
Justin T Low, Katherine B Peters
doaj +1 more source
BTK (Bruton agammaglobulinemia tyrosine kinase) [PDF]
, 2009 Review on BTK (Bruton agammaglobulinemia tyrosine kinase), with data on DNA, on the protein encoded, and where the gene is ...
van, Loo PF, Hendriks, RW
core +1 more source
Abnormalities affecting tyrosine kinase signalling in atypical myeloproliferative disorders [PDF]
, 2009 The myeloproliferative disorders (MPDs) are a group of haematopoietic stem cell diseases, characterised by proliferation of one or more cells of the myeloid lineage.
Hidalgo-Curtis, Claire
core +1 more source